EarlySight SA has extended its Seed financing round by additional CHF 3.1 million to a total of CHF 6.1 million and awaits a further top-up in the coming weeks. EarlySight’s combination of retinal imaging technology and AI-driven analysis enables early detection and improved treatment of eye diseases.

EarlySight SA 已将其种子轮融资额外增加了 310 万瑞士法郎，总额达到 610 万瑞士法郎，并预计在未来几周内进一步追加投资。EarlySight 结合视网膜成像技术和人工智能驱动的分析，能够实现眼疾的早期检测和治疗改进。

The funding will be used to launch EarlySights’s second-generation product and to progress toward U.S. regulatory approval..

这笔资金将用于推出 EarlySights 的第二代产品，并推动获得美国监管机构的批准。

Supporting precision and personalized medicine with its ophthalmic camera, boasting ten times the precision of conventional tools, and AI-driven biomarker analysis software,

以其眼科相机和比传统工具精确十倍、由人工智能驱动的生物标志物分析软件，支持精准和个性化医疗，

EarlySight

早视通

empowers researchers and clinicians with new cellular-level insights—enabling earlier, more accurate diagnoses and tailored treatment strategies.

赋予研究人员和临床医生新的细胞水平洞察力——实现更早、更准确的诊断和定制的治疗策略。

The company targets a rapidly expanding global market valued at USD 6 billion, driven by aging demographics and increasing demand for precision diagnostics and is already trusted by leading institutions such as LMU Munich, Swiss Visio Network, and Lucerne Cantonal Hospital. The company boasts a 7-digit order book with top-tier hospitals, as well as strategic collaborations with global pharmaceutical companies.

公司目标市场为一个价值60亿美元的快速扩张全球市场，该市场受到老龄化人口结构和对精准诊断需求增加的推动，并且公司已经获得了慕尼黑大学、瑞士视觉网络和卢塞恩州立医院等领先机构的信任。公司拥有七位数的顶级医院订单，并与全球制药公司建立了战略合作伙伴关系。

With over 1,000 patients scanned and a validated dataset of more than 18,000 retinal images, EarlySight’s technology is not only clinically proven but also commercially scalable—positioning the company for accelerated global growth..

通过扫描超过1000名患者并拥有经过验证的超过18000张视网膜图像的数据集，EarlySight的技术不仅在临床上得到验证，而且在商业上具有可扩展性，使公司具备加速全球增长的能力。

EarlySight’s Cellularis Discovery platform visualizes structures up to 10 times smaller than the current gold standard technology, reaching the individual cell level. This enables disease detection earlier—a critical advantage in conditions like age-related macular degeneration (AMD), where early intervention can prevent irreversible vision loss..

EarlySight的Cellularis Discovery平台能够将结构可视化，其精细程度比当前的黄金标准技术高出10倍，达到单细胞水平。这使得疾病可以更早被检测出来——在老年性黄斑变性（AMD）等病症中，早期干预能够防止不可逆的视力丧失，这是一个关键优势。

Zurich Cantonal Bank joins investor syndicate

苏黎世州银行加入投资者财团

The round includes key existing investors

本轮融资包括一些关键的现有投资者。

Verve Ventures

韵力创投

,

，

Nina Capital

妮娜资本

,

，

NovaCapital

新资本

, and

，以及

CADFEM International AG

CADFEM国际集团

, with Zurich Cantonal Bank (

`, 苏黎世州银行（`

ZKB

ZKB

) joining the syndicate as one of Switzerland’s largest and most active investors. The company is also backed by the Fondation Genevoise pour l'Innovation Technologique (

）加入财团，成为瑞士最大和最活跃的投资者之一。该公司还得到了日内瓦技术创新基金会（Fondation Genevoise pour l'Innovation Technologique）的支持。

FONGIT

方吉特

).

）。

This investment will accelerate EarlySight’s growth, enabling the launch of its second-generation product, Cellularis, and unlocking commercial collaborations with leading market players. It will also support progress toward U.S. regulatory approval of its imaging device. The investment round will remain open for further top-up investments until October..

这项投资将加速EarlySight的增长，推出其第二代产品Cellularis，并与市场领先企业展开商业合作。它还将推动其成像设备获得美国监管批准的进展。本轮投资将持续开放以接受进一步的追加投资，直至十月。

“This funding round is a steppingstone for EarlySight to become the new standard in retinal imaging. I’m thrilled to welcome Zurich Cantonal Bank and grateful for the continued support from our investors as we prepare for the scale-up phase. I’m more convinced than ever that EarlySight will improve the lives of millions affected by vision loss,” said Timothé Laforest, CEO..

“这笔融资是EarlySight成为视网膜成像新标准的垫脚石。我非常高兴欢迎苏黎世州银行，并感谢投资者们一直以来的支持，因为我们正准备进入规模化阶段。我比以往任何时候都更加坚信，EarlySight将改善数百万受视力丧失影响者的生活，”首席执行官蒂莫泰·拉福雷斯特表示。

New board members

新董事会成员

In addition, EarlySight strengthens its governance with the election of

此外，EarlySight通过选举加强了其治理能力。

Peter Aggersbjerg

彼得·阿格斯比耶

as Vice-Chairman of the Board and

作为董事会副主席和

Andy Weymann

安迪·韦曼

as Independent Director.

作为独立董事。

Peter Aggersbjerg is a seasoned international executive with over 30 years of leadership experience in MedTech and Life Science Tools. He held key roles at Mettler-Toledo GmbH, where he was leading all 5 Divisions and Global Operations and was serving on the Group Management Committee. Prior to that, he was President of Medela AG’s Breastfeeding Business Unit, and has also served as CEO of Swissimplant AG, Vernal AG, and Tytex A/S..

彼得·阿格斯比约是一位拥有超过30年领导经验的资深国际高管，专注于医疗技术和生命科学工具领域。他曾在梅特勒-托利多有限公司担任重要职务，领导所有五个部门及全球运营，并在集团管理委员会任职。在此之前，他曾任美德乐公司的母乳喂养业务部总裁，并曾担任瑞士植体公司、弗纳尔公司和泰泰克斯公司的首席执行官。

'EarlySight’s Cellularis technology detects eye diseases up to 18 months earlier, transforming patient care and clinical research. I’m thrilled to join the board and actively support the company’s next growth phase, helping bring groundbreaking vision-saving solutions to patients worldwide,' said Peter Aggersbjerg..

“EarlySight的Cellularis技术能够提前18个月检测眼部疾病，彻底改变了患者护理和临床研究。我很激动加入董事会，并积极支持公司的下一阶段增长，帮助将突破性的视力保护解决方案带给全球患者。”彼得·阿格斯比约表示。

Andy Weymann brings deep expertise in clinical strategy, market access and regulatory plus innovation, having held executive and board roles in global biotech and medtech companies and previously served as Chief Medical Officer at multinational medical equipment manufacturing company Smith+Nephew.

安迪·韦曼在临床战略、市场准入、监管以及创新方面拥有深厚的专业知识，曾在全球生物技术公司和医疗技术公司担任高管和董事会职务，并曾担任跨国医疗设备制造公司施乐辉的首席医学官。

(Press release / SK)

（新闻稿 / SK）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送